BIOMAT Database Logo BIOMAT Database Logo

Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis. 2020

Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071076 Network Meta-Analysis Meta-analysis of randomized trials in which estimates of comparative treatment effects are visualized and interpreted from a network of interventions that may or may not have been evaluated directly against each other. Common considerations in network meta-analysis include conceptual and statistical heterogeneity and incoherence. Mixed Treatment Meta-Analysis,Multiple Treatment Comparison Meta-Analysis,Meta-Analyses, Mixed Treatment,Meta-Analyses, Network,Meta-Analysis, Mixed Treatment,Meta-Analysis, Network,Mixed Treatment Meta Analysis,Mixed Treatment Meta-Analyses,Multiple Treatment Comparison Meta Analysis,Network Meta Analysis,Network Meta-Analyses
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000077982 Progression-Free Survival Length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but the disease does not get worse. Event-Free Survival,Event Free Survival,Progression Free Survival,Survival, Event-Free,Survival, Progression-Free
D000078202 Systematic Reviews as Topic Works about a review of primary literature in health and health policy that attempt to identify, appraise, and synthesize all the empirical evidence that meets specified eligibility criteria to answer a given research question. It's conducted using explicit methods aimed at minimizing bias in order to produce more reliable findings regarding the effects of interventions for prevention, treatment, and rehabilitation that can be used to inform decision making. Systematic Review as Topic,Umbrella Reviews as Topic,Reviews Systematic as Topic
D000726 Androgen Antagonists Compounds which inhibit or antagonize the biosynthesis or actions of androgens. Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen
D000736 Androstenes Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
April 2022, BJU international,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
December 2022, European urology oncology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer.
July 2021, JAMA oncology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer.
July 2021, JAMA oncology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
April 2024, European urology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
September 2023, Acta oncologica (Stockholm, Sweden),
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
April 2024, Asian journal of andrology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
May 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer-Reply.
July 2021, JAMA oncology,
Marjan Mansourian, and Khojasteh Ghasemi Ms, and Danial Khorsandi PhD, and Golnaz Vaseghi
Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
May 2024, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Copied contents to your clipboard!